Prime Medicine Inc
Research Prime Medicine Inc (PRME) on Bullrun: market cap USD 670.54M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPRME
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 670.54M
- Financial periodQ2 2026
- RevenueUSD 1.15M
- Net income-USD 42.11M
- Free cash flow-USD 41.09M
Valuation Snapshot
latest market cap is USD 670.54M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 4.63M | -USD 201.14M | -USD 167.10M | n/a | -1.35 | USD 63.03M | USD 116.43M | USD 120.87M |
| FY2024 | USD 2.98M | -USD 195.88M | -USD 130.16M | n/a | -1.65 | USD 182.48M | USD 40.79M | USD 153.15M |
| FY2023 | USD 0 | -USD 198.13M | -USD 174.14M | n/a | -2.18 | USD 41.57M | USD 13.63M | USD 133.07M |
| FY2022 | USD 0 | -USD 121.82M | -USD 147.92M | n/a | -4.19 | USD 187.62M | USD 34.72M | USD 316.27M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 670.54M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 626.38M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 382.99M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 862.29M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.81B | n/a | n/a | n/a |
About Prime Medicine Inc
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Prime Medicine Inc's market cap?
Prime Medicine Inc's market capitalization is USD 670.54M.
What does Prime Medicine Inc do?
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States.